PLoS ONE (Jan 2011)

An effective method to purify Plasmodium falciparum DNA directly from clinical blood samples for whole genome high-throughput sequencing.

  • Sarah Auburn,
  • Susana Campino,
  • Taane G Clark,
  • Abdoulaye A Djimde,
  • Issaka Zongo,
  • Robert Pinches,
  • Magnus Manske,
  • Valentina Mangano,
  • Daniel Alcock,
  • Elisa Anastasi,
  • Gareth Maslen,
  • Bronwyn Macinnis,
  • Kirk Rockett,
  • David Modiano,
  • Christopher I Newbold,
  • Ogobara K Doumbo,
  • Jean Bosco Ouédraogo,
  • Dominic P Kwiatkowski

DOI
https://doi.org/10.1371/journal.pone.0022213
Journal volume & issue
Vol. 6, no. 7
p. e22213

Abstract

Read online

Highly parallel sequencing technologies permit cost-effective whole genome sequencing of hundreds of Plasmodium parasites. The ability to sequence clinical Plasmodium samples, extracted directly from patient blood without a culture step, presents a unique opportunity to sample the diversity of "natural" parasite populations in high resolution clinical and epidemiological studies. A major challenge to sequencing clinical Plasmodium samples is the abundance of human DNA, which may substantially reduce the yield of Plasmodium sequence. We tested a range of human white blood cell (WBC) depletion methods on P. falciparum-infected patient samples in search of a method displaying an optimal balance of WBC-removal efficacy, cost, simplicity, and applicability to low resource settings. In the first of a two-part study, combinations of three different WBC depletion methods were tested on 43 patient blood samples in Mali. A two-step combination of Lymphoprep plus Plasmodipur best fitted our requirements, although moderate variability was observed in human DNA quantity. This approach was further assessed in a larger sample of 76 patients from Burkina Faso. WBC-removal efficacy remained high (70% samples) and lower variation was observed in human DNA quantities. In order to assess the Plasmodium sequence yield at different human DNA proportions, 59 samples with up to 60% human DNA contamination were sequenced on the Illumina Genome Analyzer platform. An average ~40-fold coverage of the genome was observed per lane for samples with ≤ 30% human DNA. Even in low resource settings, using a simple two-step combination of Lymphoprep plus Plasmodipur, over 70% of clinical sample preparations should exhibit sufficiently low human DNA quantities to enable ~40-fold sequence coverage of the P. falciparum genome using a single lane on the Illumina Genome Analyzer platform. This approach should greatly facilitate large-scale clinical and epidemiologic studies of P. falciparum.